Keyron Medical Technology

Founded in 2016 and based in London, UK, Keyron Medical Technology is a preclinical-stage medical device and technology platform company that provides solutions for the treatment of metabolic diseases, including type-2 diabetes, NASH, and obesity. The company was founded by its CEO, Giorgio Castagneto Gissey. In 2021, Keyron Medical Technology raised EUR 510,000 in venture funding from LIFTT. Keyron specializes in advanced medical devices aimed at reversing diabesity, diabetes, NASH, liver fibrosis, and obesity.

The company’s flagship product, the ForePass® device, represents a breakthrough in non-surgical gastric bypass procedures, utilizing a fully endoscopic method that mimics the benefits of traditional metabolic surgery without the need for incisions. The primary end-users of the ForePass® device include patients suffering from obesity and related metabolic disorders, as well as healthcare providers seeking effective treatment options. Keyron's products are designed to provide safety comparable to gastric balloons while retaining the efficacy associated with gastric bypass surgery. Keyron operates on a transactional model that primarily involves partnerships with healthcare providers and institutions.